Published in J Clin Endocrinol Metab on May 01, 2002
Graves' ophthalmopathy. N Engl J Med (2010) 4.24
Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol (2006) 1.42
Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab (2004) 1.32
Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid (2007) 1.28
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity. Lipids Health Dis (2012) 1.06
Relationship of serum thyroid stimulating hormone with body mass index in healthy adults. Indian J Endocrinol Metab (2013) 0.96
TSH stimulates adipogenesis in mouse embryonic stem cells. J Endocrinol (2008) 0.96
A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab (2013) 0.93
A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts. Thyroid (2010) 0.85
Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics (2011) 0.84
PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease. Immunogenetics (2013) 0.80
Thyrotropin and obesity: increased adipose triglyceride content through glycerol-3-phosphate acyltransferase 3. Sci Rep (2015) 0.79
Differential involvement of orbital fat and extraocular muscles in graves' ophthalmopathy. Eur Thyroid J (2013) 0.78
Isolated Subclinical Hyperthyrotropinemia in Obese Children: Does Levothyroxine (LT4) Improve Weight Reduction during Combined Behavioral Therapy? Int J Endocrinol (2015) 0.78
Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmol (2007) 0.77
Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment. Eur Thyroid J (2014) 0.76
Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy. Exp Ther Med (2016) 0.75
Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations. Eur Thyroid J (2016) 0.75
Impact of Obesity on Serum Levels of Thyroid Hormones among Euthyroid Saudi Adults. J Thyroid Res (2017) 0.75
Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev (2003) 2.23
Speed mentoring: an innovative method to facilitate mentoring relationships. Med Teach (2010) 1.52
Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol (2006) 1.42
Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab (2005) 1.40
Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab (2004) 1.32
Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab (2013) 1.29
Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid (2007) 1.28
A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol (2011) 1.27
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med (2007) 1.19
Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid (2010) 1.16
Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab (2014) 1.14
How perceived physician leadership behavior affects physician satisfaction. Mayo Clin Proc (2008) 1.08
A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab (2012) 1.08
RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res (2005) 1.07
Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metab (2003) 1.05
A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid (2012) 1.00
siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol (2005) 0.98
Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients. Am J Ophthalmol (2003) 0.97
The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid (2006) 0.94
Principles to promote physician satisfaction and work-life balance. Minn Med (2008) 0.93
Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy. Thyroid (2008) 0.93
Mentoring interdisciplinary research teams for the study of sex and gender differences in health and disease. Glob Adv Health Med (2013) 0.93
A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab (2013) 0.93
Relationships between thyroid function and lipid status or insulin resistance in a pediatric population. Thyroid (2010) 0.92
The evaluation and treatment of graves ophthalmopathy. Med Clin North Am (2012) 0.91
Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res (2003) 0.91
Signaling "cross-talk" between TGF-beta1 and ECM signals in chondrocytic cells. Cell Signal (2004) 0.91
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab (2006) 0.89
Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol (2012) 0.88
Effects of reducing the upper limit of normal TSH values. JAMA (2003) 0.87
Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase 1 promoter and outcome in patients of chondrosarcoma. Clin Cancer Res (2004) 0.86
A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts. Thyroid (2010) 0.85
Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid (2011) 0.83
Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid (2013) 0.82
Thyroid transcription factor-1 in orbital adipose tissues: potential role in orbital thyrotropin receptor expression. Thyroid (2005) 0.82
The aftermath of orbital radiotherapy for graves' ophthalmopathy. Ophthalmology (2002) 0.81
Development and application of magnetic resonance elastography of the normal and pathological thyroid gland in vivo. J Magn Reson Imaging (2009) 0.81
Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy. Arch Ophthalmol (2003) 0.80
Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease--a cohort study. Int J Cardiol (2012) 0.79
A risk prediction index for amiodarone-induced thyrotoxicosis in adults with congenital heart disease. J Thyroid Res (2012) 0.78
News and views: at long last, an animal model of Graves' orbitopathy. Endocrinology (2013) 0.77
Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. Maturitas (2013) 0.76
Direct free fatty acid storage in different sized adipocytes from the same depot. Obesity (Silver Spring) (2014) 0.75
Thyroid societies across the world. Thyroid (2008) 0.75